Conference - Newbury, United Kingdom
BioTrinity is the premier European Biopartnering and Investment Conference, partnering R&D companies with big pharma and more biomedical investors than any other European partnering conference. Check out who else is coming, including over 70 investment firms confirmed, and what they say about BioTrinity, the expert discussion panels, and which more than 70 companies will be presenting in the showcase. Don't miss out:
Meet the key licensing contacts from big pharma including Abbott, Amgen, Astellas, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Genzyme, GSK, Goldshield Group, Merck & Co., Novartis, Shire, Takeda, Teijin and Teva and other senior BD&L execs Meet 100 delegates from active VC and Corporate Venture firms including MedImmune Ventures, SR One, Shire Strategic Investment, Merck Serono Ventures, Merck Research Ventures, Abbott Biotech Ventures, Astellas Venture Management, and Boehringer Ingelheim Ventures and many international VCs Meet a hand-picked crop of early-stage companies you haven't seen elsewhere Meet the senior execs who can complete the value chain for your business
(Courtesy of BioTrinity 2013 logo, via astell.com)
BioTrinity 2013 - European Biopartnering and Investment ...
Tue, May 14, 2013 - Thu, May 16, 2013
Newbury Racecourse, Newbury, Berkshire, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
